Can a deeper cleanup beat amyloidosis?
NCT ID NCT07215494
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 50 adults with AL amyloidosis who achieved complete remission after initial chemotherapy. It checks if tiny amounts of remaining disease (called minimal residual disease, or MRD) affect organ recovery and survival. Researchers also test whether a stem cell transplant can help those with MRD live longer and better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIGHT CHAIN (AL) AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug trio tame a rare amyloid disease?
- Engineered immune cells take on rare protein disease in major trial
- Engineered immune cells take aim at a rare Protein-Clogging disease
- Personalized mutation tracking could spot relapse sooner in bone marrow cancer patients
- Cancer DNA blood test study halted before it began
- Blood test may spot hidden cancer cells, guiding smarter treatment for esophageal cancer